RT Journal Article
SR Electronic
T1 Prime hAd5 Spike + Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.05.21254940
DO 10.1101/2021.04.05.21254940
A1 Sieling, Peter
A1 King, Thomas
A1 Wong, Raymond
A1 Nguyen, Andy
A1 Wnuk, Kamil
A1 Gabitzsch, Elizabeth
A1 Rice, Adrian
A1 Adisetiyo, Helty
A1 Hermreck, Melanie
A1 Verma, Mohit
A1 Zakin, Lise
A1 Shin, Annie
A1 Morimoto, Brett
A1 Higashide, Wendy
A1 Dinkins, Kyle
A1 Balint, Joseph
A1 Peykov, Victor
A1 Taft, Justin
A1 Patel, Roosheel
A1 Buta, Sofija
A1 Martin-Fernandez, Marta
A1 Bogunovic, Dusan
A1 Spilman, Patricia
A1 Sender, Lennie
A1 Reddy, Sandeep
A1 Robinson, Philip
A1 Rabizadeh, Shahrooz
A1 Niazi, Kayvan
A1 Soon-Shiong, Patrick
YR 2021
UL http://medrxiv.org/content/early/2021/06/09/2021.04.05.21254940.abstract
AB In response to the need for a safe, efficacious vaccine that elicits vigorous T cell as well as humoral protection against SARS-CoV-2 infection, we have developed a dual-antigen COVID-19 vaccine comprising both the viral spike (S) protein modified to increase cell-surface expression (S-Fusion) and nucleocapsid (N) protein with an Enhanced T-cell Stimulation Domain (N-ETSD) to enhance MHC class I and II presentation and T-cell responses. The antigens are delivered using a human adenovirus serotype 5 (hAd5) platform with E1, E2b, and E3 regions deleted that has been shown previously in cancer vaccine studies to be safe and effective in the presence of pre-existing hAd5 immunity. The findings reported here are focused on human T-cell responses due to the likelihood that such responses will sustain efficacy against emerging variants, a hypothesis supported by our in silico prediction of T-cell epitope HLA binding for both the first-wave SARS-CoV-2 ‘A’ strain and the B.1.351 strain K417N, E484K, and N501Y spike and T201I N variants. We demonstrate the hAd5 S-Fusion + N-ETSD vaccine antigens expressed by previously SARS-CoV-2-infected patient dendritic cells elicit Th1 dominant activation of autologous patient T cells, indicating the vaccine antigens have the potential to elicit immune responses in previously infected patients. For participants in our open-label Phase 1b study of the vaccine (NCT04591717; https://clinicaltrials.gov/ct2/show/NCT04591717), the magnitude of Th-1 dominant S- and N-specific T-cell responses after a single prime subcutaneous injection were comparable to T-cell responses from previously infected patients. Furthermore, vaccinated participant T-cell responses to S were similar for A strain S and a series of spike variant peptides, including S variants in the B.1.1.7 and B.1.351 strains. The findings that this dual-antigen vaccine elicits SARS-CoV-2-relevant T-cell responses and that such cell-mediated protection is likely to be sustained against emerging variants supports the testing of this vaccine as a universal booster that would enhance and broaden existing immune protection conferred by currently approved S-based vaccines.Competing Interest StatementAll authors with an ImmunityBio, Inc. or NantKwest affiliation contributed to the conception, design, generation or testing of the vaccine described, which may become a commercial productClinical TrialNCT04591717Clinical Protocols https://www.clinicaltrials.gov/ct2/show/NCT04591717?term=QUILT&cond=COVID-19&draw=2&rank=2 Funding StatementFunded by ImmunityBio, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Western IRB for the Chan Soon-Shiong Institute for Medicine (CSSIFM) and the Hoag Hospital Providence IRB at Hoag Hospital Newport BeachAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are reported in the manuscript